H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $95.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).

The analyst commented: "Olezarsen (TRYNGOLZA) has received EU approval for familial chylomicronemia syndrome (FCS) based on BALANCE data showing durable triglyceride (TG) lowering and significant reduction in acute pancreatitis (AP). While approval in this ultra-rare setting was expected, it is strategically important, as FCS serves as a regulatory and commercial gateway to severe hypertriglyceridemia (sHTG)—a much larger market with the same biology. We believe this validation strengthens commercial positioning, builds physician familiarity, and underpins our Buy rating and 12-month price target of $95."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $61.01 yesterday.

You May Also Be Interested In

• US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
• The Government of Kenya and The Nature Conservancy Unveil US$160m Thamani Asili Community Conservation Initiative
• Uniserve Provides Vancouver Data Centre Update and Advances Canadian Digital Infrastructure Strategy